NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE · Drug Manufacturers - General · USD

GSK plc (GSK) Stock Analysis

GSK plc (GSK) is a Drug Manufacturers - General stock listed on NYSE and quoted in US Dollar.

GSK

$49.89

−$0.98 (−1.93%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare GSK with… →

GSK Key Statistics

As of Sep 4, 2026
Trading
Open
$49.70
Previous Close
$50.87
Day's Range
49.66–50.06
52-Week Range
39.29–61.70
Volume
2.29M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.29
Valuation
Market Cap
$99.92B
P/E Ratio
15.69
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
10.02
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
95.97
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3.01
EPS (ttm)Profit attributable to each share over the last twelve months.
3.18
Financials (FY)
Revenue (FY)
$32.67B+4.11%
Net Income (FY)
$5.72B+121.98%
Profit marginThe share of revenue left as profit after all costs and taxes.
14.52%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
2.00B
1-Year Return
+29.25%
Dividend and dates
Dividend
$1.82+3.57%
Ex-Dividend Date
August 14, 2026
Earnings Date
October 28, 2026estimated
Avg Volume
3.85M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

GSK Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+3.49%
2025+51.23%
2024−5.14%
2023+9.71%
2022−16.77%
2021+26.76%
2020−17.72%
2019+29.24%
2018+13.79%
2017−2.98%
2016 (partial year)−11.27%

As of September 4, 2026.

GSK Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$32.67B$5.72B17.5%
2024$31.38B$2.58B8.2%
2023$30.33B$4.93B16.2%
2022$29.32B$14.96B51.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$32.67B$23.65B$8.34B$5.72B17.5%
2024$31.38B$22.33B$5.54B$2.58B8.2%
2023$30.33B$21.76B$7.35B$4.93B16.2%
2022$29.32B$19.77B$6.73B$14.96B51.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

GSK Dividend History

$1.68+7.6% vs 2024

Dividends per share, 2025 · 4 payments

YearDividends per sharePaymentsChange
2026*$1.403—
2025$1.684+7.6%
2024$1.564+12.1%
2023$1.394−17.3%
YearDividends per sharePaymentsChange
2026 (partial year)$1.403—
2025$1.684+7.6%
2024$1.564+12.1%
2023$1.394−17.3%
2022$1.684−23.9%
2021$2.214+7.3%
2020$2.064+0.6%
2019$2.054−5.3%
2018$2.164+4.7%
2017$2.064+344.8%
2016$0.461—

Most recent payment: $0.47 per share, ex-dividend August 14, 2026. Per-share amounts summed by calendar year from ex-dividend dates. Partial years are shown muted and marked with an asterisk.

GSK Valuation vs Drug Manufacturers - General Median

Median of 21 stocks
MetricGSKDrug Manufacturers - General medianvs median
P/E15.6924.6936% below
P/S ratio3.013.134% below
Profit margin14.52%8.09%6.4 pts above

Medians across 21 Drug Manufacturers - General stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 12 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

GSK plc (GSK) is capitalised at $99.92B on the latest close. The company sits in the Healthcare sector, in the Drug Manufacturers - General industry. Headcount on file is 66,841.

Over the past 52 weeks the price has ranged from $39.29 to $61.70. GSK last closed at $49.89 on September 4, 2026. That is −$0.98 (−1.93%) against the previous close. The latest close sits 26.98% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $32.67B. That is +4.11% against the prior fiscal year, when revenue was $31.38B. The same year closed with net income of $5.72B. That is +121.98% against the prior fiscal year. The reported profit margin is 14.52%. That is 6.4 percentage points above the Drug Manufacturers - General median of 8.09%. Earnings per share on a trailing basis come to 3.18.

Across the 4 fiscal years on file, revenue moves from $29.32B in 2022 to $32.67B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 15.69 times earnings. That is 36.45% below the Drug Manufacturers - General median of 24.69. The forward P/E on file is 10.02. The PEG ratio, which sets the P/E against expected earnings growth, reads 95.97. The price-to-sales ratio is 3.01. On price-to-sales that is 3.9% below the Drug Manufacturers - General median of 3.13. The medians here are taken across 21 Drug Manufacturers - General companies that report the metric.

The reported beta is 0.29. Annualized volatility over the trailing 10 years is 22.35%. Over the trailing twelve months the price has returned +29.25%. Measured over 10 years, that is +5.91% a year compounded.

Growth & Income

The trailing dividend yield is 3.57%. That is 0.9 percentage points above the Drug Manufacturers - General median yield of 2.7%. The indicated annual rate is $1.82 a share. The ex-dividend date on file is August 14, 2026. Dividends are recorded for 11 calendar years; 2026 shows 3 payments totalling $1.40 a share. The year before, 2025, totalled $1.68 a share.

2026 is still running; the price is +3.49% year to date. Across the complete calendar years on file, 2025 returned +51.23% and 2020 returned −17.72%. Of the 9 complete calendar years on file, 5 finished higher.

Peer Comparison

GSK plc (GSK) operates in the Drug Manufacturers - General industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
GSK plc GSK $99.92B 15.7
Eli Lilly and Company LLY $1.02T 38.6
Johnson & Johnson JNJ $663.28B 32.0
AbbVie Inc. ABBV $453.19B 73.5

The Drug Manufacturers - General industry average P/E ratio is 24.7x. GSK plc trades at a P/E of 15.7.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - General Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 NVS

Novartis AG

$304.10B

 AZN

AstraZeneca PLC

$252.33B
View all Drug Manufacturers - General stocks →

Popular Healthcare Stocks

UNH

UnitedHealth Group Incorporated

$356.47B

 AMGN

Amgen Inc.

$236.38B

 TMO

Thermo Fisher Scientific Inc.

$226.94B

 NVO

Novo Nordisk A/S

$206.02B

 ABT

Abbott Laboratories

$187.45B
View all Healthcare stocks →

About GSK plc

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases; and strategic research collaboration with Engitix Ltd. to identify and validate novel therapeutic targets driving liver fibrosis regression. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.

Visit website →